Tumour mutational burden and the importance of panel size
When it comes to cancer treatment, tumour mutational burden has become increasingly utilised as a biomarker for immunotherapy response prediction — and in order to capture an accurate measurement of TMB across different cancer types and tumour loads, panel size matters.
Immunotherapy has quickly become the new pillar in cancer care, showing incredible promise for patients with various forms of cancers such as melanoma, non-small cell lung cancer (NSCLC), bladder cancer and kidney cancer among others. However, only a subset of patients benefit from these immunotherapies, and the use of predictive biomarkers is essential in stratifying patients into responders versus non-responders. The overall load of somatic mutations in the tumour, or tumour mutational burden (TMB), has become increasingly utilised as a biomarker for response prediction.
Numerous clinical studies have demonstrated that higher mutational burden correlates to improved survival benefits in patients receiving checkpoint inhibitor therapies for cancers such as melanoma, colon and NSCLC. Recent data from clinical trials such as CheckMate 227 have demonstrated that in NSCLC, higher TMB is associated with improved clinical outcomes, and there are additional trials currently underway using TMB as a biomarker.
Initial studies used whole exome sequencing (WES) as the gold standard for measuring TMB; however, cost, computational complexity and time for WES make targeted panel sequencing more attractive for routine use at present. While a variety of such gene panels of differing sizes are offered commercially, there has been very little reporting on the ideal sizes or methods of calculating TMB — until now.
Dr Albrecht Stenzinger, a pathologist at Heidelberg University Hospital, and his colleagues recently performed in-silico analysis (using combinatorial calculations and extensive simulations) of TCGA data of 8371 tumours across 25 different cancer types, including lung, melanoma, pancreatic, breast, head and neck among others. The researchers specifically investigated the influence of gene panel size on the precision of TMB measurement by considering certain core parameters, including the confidence intervals of TMB reporting, use of all mutations versus only missense mutations, and sensitivity and specificity for detection of hypermutated tumours. Their findings were recently published in the International Journal of Cancer.
The study assessed the performance parameters of two Illumina panels — TruSight Tumor 170 (TST170) and TruSight Oncology 500 (TSO500), a forthcoming panel, in the context of the in-silico analysis. The research highlights the following:
- Smaller panels result in imprecise measurement of TMB, especially for tumours with low TMB values. The data suggests that TMB estimation using small gene panels can be highly imprecise and thus clinically suboptimal for patient stratification and response prediction.
- TMB cut-off to identify hypermutated tumours is dependent on panel size, as well as on specific histology. Larger gene panels were associated with reasonable cutoff values that help identify true signals from background noise in routine diagnostics.
- Panels between 1.5 and 3 Mb were recommended to balance benefits with cost. It was also recommended that both missense and nonsense mutations are used to calculate TMB.
- TSO500 with a panel size of 1.94 Mb was shown to have good performance and is preferable for TMB measurement over TST170.
“Studies such as this highlight the importance of panel size to the accurate measurement of TMB across different cancer types and tumour loads,” said Dr Phil Febbo, Chief Medical Officer at Illumina. “To the best of my knowledge, this is the first publication to use large-scale computational analysis to evaluate how size of the gene panel, and the type of mutations included in the calculations, impacts measurement of TMB.
“Of course, algorithms for mutation calling and filters to remove artefacts and germline variants are also components of accurate TMB, but this paper will contribute significantly to ongoing efforts working to standardise TMB as a biomarker.”
The non-invasive method relies on an algorithm to analyse patient stool samples, which contain...
Researchers have developed a graphene oxide-based sensor platform to detect acute infections...
Researchers developed a simple agglutination assay to detect the presence of antibodies raised in...